Brief: Immuneonco Biopharmaceuticals Shanghai Says Approval By NMPA For Phase III Clinical Trial
17/04/2024 12:07
April 17 (Reuters) - ImmuneOnco Biopharmaceuticals
Shanghai Inc 1541.HK :
* APPROVAL BY NMPA FOR PHASE III CLINICAL TRIAL PROTOCOL OF
IMM01
(TIMDARPACEPT)
Further company coverage: 1541.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ImmuneOnco Biopharmaceuticals (Shanghai)
See all newsBrief: Immuneonco Biopharmaceuticals (Shanghai) To Subscribe For Wealth Management Product For Hk$87.5 Million
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S